Cite
APA Citation
Corrie, P., Terheyden, P., ten Tije, A., Herbst, R., Jansen, R., Marples, M., Debus, D., Marconcini, R., Blasinska‐Morawiec, M., Freivogel, K., Munson, M., Goodman, G., Hsu, J., Sadetsky, N., Colburn, D., & Rutkowski, P. (2019). a prospective observational safety study of patients with BRAFV600‐mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study). British journal of dermatology, 180, 1254–1255. http://access.bl.uk/ark:/81055/vdc_100081461584.0x000064